Abstract
Prior studies of advanced non-small cell lung cancer (adv NSCLC) in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database have shown that a majority of patients did not receive infused systemic anticancer treatment (SATx). More recently, innovations in SATx have favored patients with nonsquamous (NSQ) histology and have expanded to include oral targeted therapies. This study examines oral and infused SATx by line of therapy (LOT) and histology in a more recent population-based cohort.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
